The CLSTN1 antibody targets the calsyntenin-1 protein, a member of the calsyntenin family of type I transmembrane proteins predominantly expressed in the nervous system. Calsyntenin-1 (CLSTN1), also known as alcadein-α, plays roles in synaptic function, intracellular trafficking, and neuronal signaling. It interacts with presenilin, a protein linked to Alzheimer’s disease, suggesting involvement in amyloid precursor protein processing and pathological pathways. CLSTN1 antibodies are critical tools in neuroscience research, enabling the detection and localization of CLSTN1 in brain tissues or cultured neurons via techniques like immunohistochemistry, Western blotting, and immunofluorescence. Studies using these antibodies have explored CLSTN1's distribution in synaptic regions, its role in cognitive functions, and potential dysregulation in neurodegenerative disorders. Commercially available CLSTN1 antibodies are typically raised against specific epitopes, such as the extracellular or cytoplasmic domains, and require validation for species reactivity (e.g., human, mouse) and application specificity. Recent research highlights CLSTN1's interaction with kinesin motors in axonal transport and its modulation of GABAergic signaling, underscoring its multifaceted contributions to neural circuitry and disease mechanisms.